Recent News

• 03.17.2025 - Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call
• 03.10.2025 - Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
• 02.06.2025 - Dror Bashan Interview
• 02.04.2025 - Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
• 02.04.2025 - Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
• 12.23.2024 - Protalix BioTherapeutics Issues 2025 Letter to Stockholders
• 12.09.2024 - Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
• 11.14.2024 - Protalix Third Quarter 2024 Financial and Business Results Conference Call
• 11.14.2024 - Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
• 11.07.2024 - Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Recent Filings

• 12.31.2024 - 8-K Current report
• 12.23.2024 - EX-99.1 EX-99.1
• 12.23.2024 - 8-K Current report
• 11.14.2024 - EX-99.1 EX-99.1
• 11.14.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2024 - 8-K Current report
• 11.05.2024 - 4/A Statement of changes in beneficial ownership of securities
• 10.25.2024 - EX-99.1 EX-99.1